



## **General Test Requisition Form - Biochemical and Molecular**

Please complete every field and tick box clearly.

PATIENT INFORMATION			PATIENT SAMPLE INFORM	MATION			
		MM/ DD /YYYY	SAMPLE TYPE:	Collec	ction Date: <u>MM/</u> [	DD/YY	
Patient's First Name	Middle Initial	Patient's Date of Birth	○ Saliva Swab	Was t	his sample collec	cted in NY State: O Yes O No	
T dients i list Name		T dilett 3 Date of Birth	○Whole Blood				
			O Dried Blood Spots				
Patient's Last Name	Patient ID/MR N	lumber	Other	_			
Biological Sex: OMale OFemale OUnkno	own		INDICATION FOR TESTING	G (Required)			
Gender Identity (if different from above):			ICD10 Code(s):				
			Clinical Diagnosis:		_		
Patient's Street Address			Age at Initial Presentation:				
			BIOCHEMICAL TESTS				
City / Town State	Zip C	Code	SCREENING PANELS				
	· · ·			hansiya Disah	amical Drafilat		
Country Patient's Prei	ferred Phone		OB0200 StepOne® Compre			0.	
			Birth Time: Weeks' Gestation:				
Patient's Email			Transfusion status: O Ye		_ birtir vveigitt.		
	American OA	sian (China Janan Karas)	If yes, transfusion type:		Date:	Time:	
Ethnicity (check all that apply): African-A		sian (China, Japan, Korea)	, so, transidolori type.	O Plasma		Time:	
OCaucasian/N. European/S. European OF	innish	OFrench Canadian		ORBC		Time:	
OHispanic OJewish - Ashkenazi OJ	ewish - Sephardio	OMediterranean	†DBS Only				
OMiddle Eastern	lative American	○E. Indian					
(Saudi Arabia, Qatar, Iraq, Turkey)		OL. Illulari	○B0210 Acylcarnitine Profile ○B2020 Amino Acid Profile	е			
OSoutheast Asian (Vietnam, Cambodia, Thailand	) OSouth	Asian (India, Pakistan)	○ B2040 Lysosomal Storage Disease Enzyme Panel				
Other (specify)			OB0024 Post-Mortem Scree		-,		
ODDERING PROVIDER			DIAGNOSTIC AND MONIT	ORING PANE	ELS		
ORDERING PROVIDER			○B0009 Galactosemia Mon	itoring			
			OB0018 PKU Clinical Monit	oring			
Provider's First and Last Name			OB0022 Tyrosinemia Monito	oring			
			COMPREHENSIVE NEWBO	ODN TESTIN	C		
PKIG Ordering Provider Account Number	NPI						
Olinia II I a ani ta I II anti ta tinan Nama			<ul><li>D3005 NeoSeq Newborn</li><li>D3004 Expanded Newborr</li></ul>		•	uncing Toet	
Clinic/Hospital/Institution Name			O D 3004 Expanded Newborr	i Screening (iv	ibo) Gerie Seque	ricing lest	
Du Mada Facili			ADDITIONAL TESTING <sup>†</sup>				
Provider's Email	Provider's Ph	ione	Test Code:				
Danisidada Charat Addana			Test Name:				
Provider's Street Address			<sup>†</sup> Additional testing options in	ncluding DNA	Mutation Screen	as and Gene Sequencing	
City / Trans		) - d -	for individual conditions (or				
City / Town State	Zip C	ode	For single gene testing, plea	ise order test	code D3100 - Ar	nvGene™ Test: Single Gene	
			Sequencing and Del/Dup Te	st. Please sub	omit requested g	ene for testing at	
Country Provider's Fa			apps.perkinelmergenomics.c	com/genelist a	and include custo	om gene ID with request.	
SEND ADDITIONAL COPY OF RESULTS TO	(If applicable)						
Name	_						
PKIG Ordering Provider Account Number	Phone Numb	per					
Email Address	Fax Number						
PHYSICIAN CONFIRMATION OF INFORMED							
The undersigned person (or representative thereinformed consent for the testing ordered, includin for the patient. Furthermore, all information on thi	g a discussion of th	ne benefits and limitations. I	confirm that testing is medically ne	ecessary and t	hat test results ma	ay impact medical management	
0		Data					
Signature		Date					

FOR INTERNAL USE ONLY					
Date Rec'd Rec'd					
TEMP	SPEC	COL	#TUBES	VOL	
R/C/F					
R/C/F					
R/C/F					





# **General Test Requisition Form - Biochemical and Molecular**

■ INSTITUTIONAL BILLING					
Institution/Organization Name			PerkinElmer Genomics Billing Account ID		
Contact Name			Contact Phone		
■ PATIENT (SELF) PAYMENT					
By providing payment information, you are authorizing PerkinElr is required prior to test initiation. The patient's sample will be platest order may be canceled. Please note that failure by the patie	aced on hold (for up to 30 days) unt	il payment i	s secured. If the patient does not provide payment to Per	rkinElmer within 3	0 days, the
O CHECK: \$ Amount Enclosed (Please r	make checks payable to: Perkin	Elmer Ger	etics, Inc.)		
O CREDIT CARD (Please fill out all information):					
	MM/YY				
Credit Card Number	Card Exp. Date CVV	Ca	rdholder Printed Name as Appears on Card	Amount	
Credit Card Billing Street Address		City / Town		State	Zip Code
Cardholder Signature			Cardholder Phone		
O CONTACT PATIENT FOR PAYMENT INFORMATION	I				
Mobile Phone			Home Phone		
Email Address					





## General Test Requisition Form - Biochemical and Molecular

DETAILED MEDICAL RECORDS, CLINICAL SUMMARY, PICTURES AND FAMILY HISTORY MUST BE ATTACHED FOR ALL CASES.

CLINICAL INFORMATION IS CRUCIAL FOR ACCURATE INTERPRETATION OF RESULTS.

ADDITIONAL OPTIONAL PHENOTYPE / PATIENT HISTORY SECTION (Check all that apply)

Clinical diagnosis: Age of manifestation: ICD-10 Codes: A. NEUROLOGY **B. METABOLISM** 2. Skin and integument 3. Endocrine 1. Behavioral abnormality O 1. Abnormal creatine kinase O 2.1 Abnormal skin pigmentation O 3.1 Diabetes mellitus O 1.1 Autism O 2. Decreased plasma carnitine O 2.2 Abnormal hair O 3.2 Hypo / hyperparathyroidism O 1.2 Attention deficit disorder O 3. Hyperalaninemia O 2.3 Abnormal nail O 3.3 Hypo / hyperthyroidism O 1.3 Psychiatric diseases O 4. Hypoglycemia O 2.4 Hyperextensible skin H. REPRODUCTION O 5. Increased CSF lactate O 2.5 Ichthyosis O 1. Abnormal external genitalia 2. Brain imaging O 2.1 Abnormal myelination O 6. Increased serum pyruvate F. CARDIOVASCULAR O 2. Abnormal internal genitalia O 2.2 Abnormal cortical gyration O 7. Ketosis O 1. Angioedema O 3. Hypogonadism O 2.3 Agenesis of corpus callosum O 8. Lactic acidosis O 2 Aortic dilatation O 4. Hypospadias O 3. Arrhythmia O 2.4 Brain atrophy O 9. Organic aciduria O 5. Infertility O 2.5 Cerebellar hypoplasia C. EYE O 4. Coarctation of aorta I. ONCOLOGY O 1. Blepharospasm O 5. Defect of atrial septum O 2.6 Heterotopia O 1. Adenomatous polyposis O 2.7 Holoprosencephaly O 2. Cataract O 6. Defect of ventricular septum O 2. Breast carcinoma O 2.8 Hydrocephalus O 3. Coloboma O 7. Dilated cardiomyopathy O 3. Colorectal carcinoma O 2.9 Leukodystrophy O 4. Glaucoma O 8. Hypertension O 4. Leukemia O 2.10 Lissencephaly O 5. Microphthalmos O 9. Hypertrophic cardiomyopathy O 5. Myelofibrosis 3. Developmental delay O 6. Nystagmus O 10. Hypotension O 6. Neoplasm of the lung O 3.1 Delayed motor development O 7. Ophthalmoplegia O 11. Lymphedema O 7. Neoplasm of the skin O 8. Optic atrophy O 12. Malf. of heart and great vessels O 3.2 Delayed language development O 8. Paraganglioma O 3.3 Developmental regression O 9 Ptosis O 13. Myocardial infarction O 9. Pheochromocytoma O 3.4 Intellectual disability O 14. Stroke J. HEMATOLOGY AND IMMUNOLOGY O 10. Retinitis pigmentosa O 15. Tetralogy of Fallot O 11. Retinoblastoma 4. Movement abnormality O 1. Abnormality of coagulation O 4 1 Ataxia O 12 Strabismus O 16. Vasculitis O 2. Anemia O 4.2 Chorea O 13. Visual impairment O 3. Immunodeficiency G. GASTROINTESTINAL. GENITOURINARY, ENDOCRINE O 4.3 Dystonia D. MOUTH, THROAT AND EAR O 4 Neutropenia O 4 4 Parkinsonism O 1. Abnormality of dental color 1. Gastrointestinal O 5. Pancytopenia O 2. Cleft lip / palate 5. Neuromuscular abnormality O 1.1 Aganglionic megacolon O 6. Abnormal hemoglobin O 1.2 Constipation O 5.1 Muscular hypotonia O 3. Conductive hearing impair. O 7. Splenomegaly O 5.2 Muscular hypertonia O 4. External ear malformation O 1.3 Diarrhea O 8. Thrombocytopenia O 1.4 High hepatic transaminases K. PRENATAL AND DEVELOPMENT O 5.3 Hyperreflexia O 5. Hypodontia O 5.4 Spasticity O 6. Sensoneural hearing impair. O 1.5 Gastroschisis O 1. Dysmorphic facial features O 1.6 Hepatic failure 6. Seizures O 2. Failure to thrive E. SKIN. INTEGUMENT AND SKELETAL O 6.1 Febrile seizures O 1.7 Hepatomegaly O 3. Hemihypertrophy 1. Skeletal O 6.2 Focal seizures O 1.8 Obesity O 4. Hydrops fetalis O 1.1 Abnormal limb morphology O 6.3 Generalized seizures O 1.9 Pyloric stenosis O 5. IUGR O 1.2 Abnormal skeletal system O 1.10 Vomiting 7. Others O 6. Oligohydramnios O 1.3 Abnormal vertebral column 2. Genitourinary O 7.1 Craniosynostosis O 7. Overgrowth O 1.4 Joint hypermobility O 72 Dementia O 2.1 Abnormal renal morphology O 8. Polyhydramnios O 1.5 Multiple joint contractures O 9. Premature birth O 7.3 Encephalopathy O 2.2 Abnormal urinary system O 1.6 Polydactyly O 7.4 Headache / Migraine O 2.3 Hydronephrosis O 10. Short stature O 1.7 Scoliosis O 7.5 Macrocephaly O 2.4 Renal agenesis O 11. Tall stature O 7.6 Microcephaly O 1.8 Syndactyly O 2.5 Renal cyst O 1.9 Talipes equinovarus O 7.7 Neuropathy O 2.6 Renal tubular dysfunction

OTHER:

O 7.8 Stroke





Associated Condition(s) Test Type		Test Name	Test Code	Sample Type	
		AMINO ACID, ORGANIC ACID, FATTY ACID OXIDATION DISORDERS			
Multiple	Biochemical Assay	Acylcarnitine Profile	B0210	DBS, WB, gDNA	
Multiple	Biochemical Assay	Amino Acid Profile	B2020	DBS, WB, gDNA	
2,4 Dienoyl-CoA Reductase Deficiency (DE RED)	Full Gene Analysis	NADK2 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
2-methylbutyryl Glycinuria	Full Gene Analysis	ACADSB Gene Sequencing	D3100	DBS, WB, SV, gDNA	
3-methylcrotonyl-CoA Carboxylase Deficiency (3-MCC Deficiency)	Targeted Variant Testing	3-MCC Deficiency Mutation Panel	D0410	DBS	
3-methylglutaconic Aciduria, Type I	Full Gene Analysis	AUH Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Argininemia	Full Gene Analysis	ARG1 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Argininosuccinic Aciduria	Full Gene Analysis	ASL Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Beta-ketothiolase Deficiency	Full Gene Analysis	ACAT1 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Carnitine Palmitoyltransferase I Deficiency	Full Gene Analysis	CPT1A Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Carnitine Palmitoyltransferase II Deficiency	Full Gene Analysis	CPT2 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Carnitine Uptake Defect (CUD)	Full Gene Analysis	SLC22A5 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Carnitine-acylcarnitine Translocase (CACT) Deficiency	Full Gene Analysis	SLC25A20 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Citrullinemia Type I	Full Gene Analysis	ASS1 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Citrullinemia Type II	Full Gene Analysis	SLC25A13 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Cobalamin C Deficiency	Full Gene Analysis	MMACHC Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Cobalamin D Deficiency	Full Gene Analysis	MMADHC Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Glutaric Acidemia Type I	Targeted Variant Testing	Glutaric Acidemia Type I Mutation Panel	D0406	DBS	
Glutaricaciduria, Type I	Full Gene Analysis	GCDH Gene Sequencing	D3100	DBS, WB, SV, gDNA	
HMG-CoA Lyase Deficiency	Full Gene Analysis	HMGCL Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Homocystinuria	Full Gene Analysis	CBS Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Hypermethioninemia	Full Gene Analysis	ADK Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Isobutyryl-CoA Dehygrogenase Deficiency	Full Gene Analysis	ACAD8 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Isovaleric Acidemia	Targeted Variant Testing	Isovaleric Acidemia Mutation Panel	D0409	DBS	
Isovaleric Acidemia	Full Gene Analysis	IVD Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency (LCHADD)	Targeted Variant Testing	LCHADD Mutation Panel	D0407	DBS	
Maple Syrup Urine Disease	Targeted Variant Testing	Maple Syrup Urine Disease Mutation Panel	D0401	DBS	
Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)	Targeted Variant Testing	MCADD Mutation Panel	D0400	DBS	
Medium-chain Acyl-CoA Dehydrogenase Deficiency (MCADD)	Full Gene Analysis	ACADM Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Methylmalonic Acidemia	Targeted Variant Testing	Methylmalonic Acidemia Mutation Panel	D0411	DBS	
Methylmalonic Acidemia	Full Gene Analysis	MUT Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Multiple Carboxylase Deficiency	Full Gene Analysis	HLCS Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Multiple Sulfatase Deficiency	Full Gene Analysis	SUMF1 Gene Sequencing	D3100	DBS, WB, SV, gDNA	
Phenylketonuria (PKU)	Biochemical Assay	PKU Monitoring - Phenylalanine	B0018	DBS, WB	
Phenylketonuria (PKU)	Full Gene Analysis	PAH Gene Sequencing		DBS, WB, SV, gDNA	
Propionic Acidemia	Targeted Variant Testing	Propionic Acidemia Mutation Panel	D0412	DBS	
Short Chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency (M/SCHADD)	Full Gene Analysis	HADH Gene Sequencing		DBS, WB, SV, gDNA	
Short-chain Acyl-CoA Dehydrogenase Deficiency (SCADD)	Full Gene Analysis	ACADS Gene Sequencing	D3100	DBS, WB, SV, gDNA	





Associated Condition(s)	Test Type	Test Name	Test Code	Sample Type
Tyrosinemia	Biochemical Assay	Tyrosinemia Monitoring - Succinylacetone and Tyrosine		DBS, WB
Tyrosinemia Type I	Full Gene Analysis	FAH Gene Sequencing		DBS, WB, SV, gDNA
Tyrosinemia Type I	Biochemical	Succinylacetone (SUAC)		DBS, WB, gDNA
Tyrosinemia Type II	Full Gene Analysis	TAT Gene Sequencing	D3100	DBS, WB, SV, gDNA
Tyrosinemia Type III	Full Gene Analysis	HPD Gene Sequencing	D3100	DBS, WB, SV, gDNA
Very Long-chain Acyl-CoA Dehydrogenase Deficiency (VLCADD)	Full Gene Analysis	ACADVL Gene Sequencing	D3100	DBS, WB, SV, gDNA
		BIOTINIDASE DEFICIENCY	_	
Biotinidase Deficiency	Biochemical Assay	Biotinidase Deficiency (Complete/Partial) - Biotinidase Deficiency Enzyme Analysis	B0001	DBS
Biotinidase Deficiency	Targeted Variant Testing	Biotinidase Deficiency Mutation Panel	D0402	DBS
Biotinidase Deficiency	Full Gene Analysis	BTD Gene Sequencing	D3100	DBS, WB, SV, gDNA
		CYSTIC FIBROSIS		
Cystic Fibrosis	Biochemical Assay	IRT Analysis (Not valid after 90 days of age)	B0005	DBS
Cystic Fibrosis	Targeted Variant Testing	Cystic Fibrosis Mutation Panel	D3100	DBS
Cystic Fibrosis	Full Gene Analysis	CFTR Gene Sequencing	D3100	DBS, WB, SV, gDNA
	<u>'</u>	DUCHENNE MUSCULAR DYSTROPHY		
Duchenne Muscular Dystrophy (DMD)	Biochemical Assay	Duchenne Muscular Dystrophy Creatine Kinase Activity	B0006	DBS
Duchenne Muscular Dystrophy (DMD)	Full Gene Analysis	DMD Gene Sequencing and Del/Dup Testing		DBS, WB, SV, gDNA
Duchenne Muscular Dystrophy (DMD)	Deletion/ Duplication	DMD Del/Dup Testing	D5125	DBS, WB, SV, gDNA
	Analysis	EDIEDDEICHIS ATAYIA		
Friedreich's Ataxia	Tandem Repeat	FRIEDREICH'S ATAXIA  FXN Repeat Analysis	D5133	DBS, WB, gDNA
Theureich's Ataxia	Analysis	17 ATV Repeat Analysis	D3133	DBS, WB, gBNA
		GALACTOSEMIA		
Galactosemia	Biochemical Assay	Galactosemia Monitoring - Galactose-1-phosphate uridyltransferase Enzyme Analysis and Total Galactose	B0009	DBS
Galactosemia	Targeted Variant Testing	Galactosemia Mutation Panel	D0405	DBS
Galactosemia	Full Gene Analysis	GALT Gene Sequencing	D3100	DBS, WB, SV, gDNA
Galactoepimerase Deficiency	Full Gene Analysis	GALE Gene Sequencing	D3100	DBS, WB, SV, gDNA
Galactokinase Deficiency	Full Gene Analysis	GALK Gene Sequencing	D3100	DBS, WB, SV, gDNA
		GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY		
Glucose-6-phosphate Dehyrogenase Deficiency	Biochemical Assay	Glucose-6-phosphate Dehyrogenase Deficiency (screening only)	B0011	DBS
Glucose-6-phosphate Dehyrogenase Deficiency	Targeted Variant Testing	Glucose-6-phosphate Dehyrogenase Deficiency Mutation Panel	D0404	DBS
Glucose-6-phosphate Dehyrogenase Deficiency	Full Gene Analysis	G6PD Gene Sequencing		DBS, WB, SV, gDNA
		LYSOSOMAL STORAGE DISORDERS - TESTING OPTIONS	_	
Lysosomal Storage Disorders	Biochemical Assay	Lysosomal Storage Disease Enzyme Panel	B2040	DBS, WB
Lysosomal Storage Disorders	Full Gene Analysis	Lysosomal Storage Disorder Gene Sequencing Panel (12 Genes)		DBS, WB, SV, gDNA
Fabry Disease	Biochemical Assay	Alpha-Galactosidase A Enzyme Analysis	B0007	DBS, WB
Fabry Disease	Biochemical Assay	Globotriaosylsphingosine (lyso-Gb3) Monitoring	B0029	DBS, WB
Fabry Disease	Full Gene Analysis	ysis GLA Gene Sequencing D5033		DBS, WB, SV, gDNA
Gaucher Disease	Biochemical Assay	Glucocerebrosidase (Glucosylceramidase) Enzyme Analysis	B0010	DBS, WB
Gaucher Disease	Biochemical Assay	Glucosylsphingosine (lyso-Gb1) Monitoring	B0030	DBS, WB
Gaucher Disease	Full Gene Analysis	sis GBA Gene Sequencing D5032 D		DBS, WB, SV, gDNA
Krabbe Disease	Biochemical Assay	Galactocerebrosidase Enzyme Analysis	B0012	DBS, WB





Associated Condition(s)	Test Type	Test Name	Test Code	Sample Type
Krabbe Disease	Biochemical Assay	Psychosine Biochemical Assay	B0028	DBS, WB
Krabbe Disease	Full Gene Analysis	GALC Gene Sequencing	D5031	DBS, WB, SV, gDNA
MPS I (Hurler Syndrome)	Biochemical Assay	Alpha-L-Iduronidase Enzyme Analysis	B0013	DBS, WB
MPS I (Hurler Syndrome)	Full Gene Analysis	IDUA Gene Sequencing	D5041	DBS, WB, SV, gDNA
MPS II (Hunter Syndrome)	Biochemical Assay	Iduronate 2-Sulfatase Enzyme Analysis	B0014	DBS, WB
MPS II (Hunter Syndrome)	Full Gene Analysis	IDS Gene Sequencing	D5042	DBS, WB, SV, gDNA
MPS IVA (Morquio A Syndrome)	Biochemical Assay	Galactosamine-6-Sulfatase Enzyme Analysis	B0015	DBS, WB
MPS IVA (Morquio A Syndrome)	Full Gene Analysis	GALNS Gene Sequencing	D5028	DBS, WB, SV, gDNA
MPS IVB (GM1 Gangliosidosis)	Biochemical Assay	β-galactosidase Enzyme Analysis	B0025	DBS, WB
MPS IVB (GM1 Gangliosidosis)	Full Gene Analysis	GLB1 Gene Sequencing	D5034	DBS, WB, SV, gDNA
MPS VI (Maroteaux-Lamy Syndrome)	Biochemical Assay	Arylsulfatase B Enzyme Analysis	B0016	DBS, WB
MPS VI (Maroteaux-Lamy Syndrome)	Full Gene Analysis	ARSB Gene Sequencing	D5009	DBS, WB, SV, gDNA
MPS VII (Sly Syndrome)	Biochemical Assay	β-glucuronidase Enzyme Analysis	B0026	DBS, WB
Mucopolysaccharidosis VII	Full Gene Analysis	GUSB Gene Sequencing	D5035	DBS, WB, SV, gDNA
Multiple Sulfatase Deficiency	Full Gene Analysis	SUMF1 Gene Sequencing	D5058	DBS, WB, SV, gDNA
Niemann Pick Disease Types A and B	Biochemical Assay	ACID Sphingomyelinase Enzyme Analysis	B0017	DBS, WB
Niemann Pick Disease Types A and B	Full Gene Analysis	SMPD1 Gene Sequencing	D5057	DBS, WB, SV, gDNA
Pompe Disease	Biochemical Assay	ACID Alpha-Glucosidase Enzyme Analysis	B0019	DBS, WB
Pompe Disease	Full Gene Analysis	GAA Gene Sequencing	D5025	DBS, WB, SV, gDNA
Neuronal Ceroid Lipofuscinosis 2 (CLN2)	Biochemical Assay	Tripeptidyl peptidase 1 Enzyme Analysis	B0027	DBS, WB
Neuronal Ceroid Lipofuscinosis 2 (CLN2)	Full Gene Analysis	TPP1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
, ,		SEVERE COMBINED IMMUNODEFICIENY		
Severe Combined Immunodeficiency (SCID)	Molecular DNA Screen	TREC Assay	D0416	DBS
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	ADA Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	AK2 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	ATM Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	CD3D Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	CD3E Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	CD3Z Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	CORO1A Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	DCLRE1C (Artemis) Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	DOCK8 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	FOXN1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	IL2RG SGene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	ILTR Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	JAK3 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	LIG4 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	NHEJ1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	ORAI1 Gene Sequencing	D3100	DBS, WB, SV, gDNA





Associated Condition(s)	Test Type	Test Name	Test Code	Sample Type
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	PNP Gene Sequencing		DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	PRKDC Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	PTPRC Gene Sequencing D31		DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	RAC2 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	RAG1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	RAG2 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	RMRP Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	STIM1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	TBX1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Severe Combined Immunodeficiency (SCID)	Full Gene Analysis	ZAP70 Gene Sequencing		DBS, WB, SV, gDNA
		SICKLE CELL AND OTHER HEMOGLOBINOPATHIES		
Sickle Cell and Other Hemoglobinopathies	Biochemical Assay	Isoelectric Focusing GEL Electrophoresis of Hemoglobiins		DBS
Sickle Cell and Other Hemoglobinopathies	Targeted Variant Testing	Sickle Cell and Other Hemoglobinopathies Mutation Panel	D0408	DBS
		SPINAL MUSCULAR ATROPHY (SMA)		
Spinal Muscular Atrophy (SMA)	Deletion/ Duplication Analysis	SMA Diagnostic Test	D5134	DBS, WB, gDNA
Spinal Muscular Atrophy (SMA)	Deletion/ Duplication Analysis	SMA Carrier Screen	D5135	DBS, WB, gDNA
Spinal Muscular Atrophy (SMA)	Deletion/ Duplication Analysis	SMN2 Copy Number Test	D5136	DBS, WB, SV, gDNA
		OTHER		
Congenital Adrenal Hyperplasia (CAH)	Biochemical Assay	Congenital adrenal hyperplasia - 17A Hydroxyprogesterone (17 OHP)	B0002	DBS
Congenital Adrenal Hyperplasia (CAH)	Full Gene Analysis	CYP21A2 Gene Sequencing and Del/Dup Testing (by MLPA)	D5019	DBS, WB, SV, gDNA
Congenital Hypothyroidism	Biochemical Assay	Thyroid-Stimulating Hormone (TSH)	B0003	DBS
Congenital Hypothyroidism	Biochemical Assay	Thyroxine (T4)	B0004	DBS
Fragile X	Triplet Repeat Testing	FMR1 Triplet Repeat (CGG) Testing	D4042	DBS, WB, SV, gDNA
X-linked Adrenoleukodystrophy	Biochemical Assay	X-Linked Adrenoleukodystrophy - C26:0 Lysophosphatidylcholine B00		DBS, WB
X-linked Adrenoleukodystrophy	Full Gene Analysis	ABCD1 Gene Sequencing	D3100	DBS, WB, SV, gDNA
Multiple	Biochemical Assay	Post Mortem - Includes: 17-Hydroxyprogesterone, Acylcarnitines, Galactose, and <i>TSH</i>	B0024	DBS

DBS = Dried Blood Spots, WB = Whole Blood, SV = Saliva Swab, gDNA = Genomic DNA





### U.S. CLINICAL INFORMED CONSENT FORM

PerkinElmer Genetics, Inc., ("PerkinElmer") requires a completed Patient's Informed Consent Form (ICF) for testing to be performed. The ICF must be completed by the patient, or a legally authorized representative of the patient (or by the healthcare provider where permitted under applicable law or regulation). For any patient below the age of majority, the ICF must be completed by the patient's legally authorized representative.

The purpose of this ICF is to provide you with a description of the Test ordered, known risks and benefits of the Test, anonymization of personal health information ("PHI"), sample and data retention, research opportunities, and the reporting of secondary findings, if applicable. Given the complexity of the type of the Test, it is recommended that you and/or your child receive genetic counseling by a trained genetics professional before and after the testing is performed.

#### **TEST INFORMATION**

Your healthcare provider ("HCP") has recommended that you, or your child, receive enzymatic, biochemical or molecular genetics clinical testing ("Test") indicated on the submitted Test Requisition Form ("Requisition"). For more information on the reasons your HCP has ordered the Test, and the disorders your HCP is having you tested for, please consult with your HCP. You are free to decide if you want this Test performed or not. Providing a Sample and undergoing the Test is voluntary and you may withdraw your consent without penalty at any time.

Enzyme/Biomarker Test: This type of test measures the presence or absence of enzymes/biomarkers and/or their level of activity in an individual. Only the enzymes/biomarkers identified on the requisition will be tested. Results from this type of Test may indicate the presence of a specific condition or conditions, and follow-up confirmatory testing may be recommended.

Genetic/Genomic Test: This type of Test analyzes one or more segments of your DNA depending on the assay requested. This Test is used to identify what, if any, DNA variant(s) you or your child is carrying which is causing the specific disease or condition you are being tested for. Identifying the mutation may be useful for diagnostic and treatment purposes, and allows at-risk family members to be tested. Only the genes identified on the Requisition will be analyzed. In some cases, we may not be able to determine with certainty which gene is actually causing the disease.

### **TEST METHOD**

If you consent to the Test, your HCP will take a sample of your and/or your child's blood, saliva, body fluid, tissue or other sample type. Your Sample will be sent to PerkinElmer's laboratories in the United States for the Test; the majority of testing will be performed at our laboratory headquarters in Pittsburgh, PA.

Under some circumstances, including inadequate or poor quality sample, an additional Sample may be required for Tests to be performed.

#### **TEST RESULTS**

Your treating HCP has sole responsibility for all decisions concerning the possible management of your diagnosis and disease; PerkinElmer will not provide a diagnosis. PerkinElmer will report Test results only to your HCP via secure email, a secure internet portal, or fax. Your HCP is responsible for communicating with you regarding the results of the Test and may refer you or your child to a specialist for further clinical evaluation and confirmation of diagnosis, if applicable. Possible results for Genetic/Genomic Tests include:

- 1. Positive: A positive genetic test result may indicate that you are a carrier of, predisposed to, or have the specific disease or condition being tested for. A positive genetic test may limit your access to health insurance or life assurance coverage; for example, a life insurance company might ask you to provide genetic information indicating a disorder if this information is available to you.
- 2. Negative: A negative result indicates that no disease-causing variant was identified in the Test performed. No Test can rule out all genetic diseases or conditions. A negative result does not guarantee that you are free from genetic disorders or other medical conditions.
- 3. Inconclusive/Variant of Uncertain Significance: A variant of uncertain significance (VOUS) result indicates that a DNA change was detected, but it is currently unknown if the variant is associated with a genetic disorder. A VOUS is not the same as a positive result and does not clarify whether there is an increased risk to develop a genetic disorder. The variant could be a benign change or it could be indicative of disease/disease-causing.
- 4. Unexpected Results: In rare instances, this Test may reveal an important genetic change that is not directly related to the reason for ordering this test. This information would be disclosed to your HCP if it potentially impacts medical care, and you have consented to receive this type of result

#### TEST REPORT

Reported disease-causing variants are described as pathogenic variant(s), likely pathogenic variants(s), or variant(s) of uncertain significance in genes interpreted to be responsible for, or potentially contributing to, a disease or condition. In addition, variants in genes not known to be associated with disease but for which there is evidence to suggest an association with disease may also be reported. For testing performed on prenatal samples or for screening of apparently healthy individuals, only variants classified as pathogenic or likely pathogenic will be reported.

When Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) tests are ordered by your HCP, you have the option to receive some findings not directly related to the reason for ordering the Test called "Secondary Findings". When Secondary Findings are requested, only Pathogenic or Likely Pathogenic findings will be reported, where applicable. Please read the Secondary Findings sections on page 3 and/or 4 of this consent form for more information, and available reporting options. For prenatal samples, secondary findings for the proband are not available.

### INFORMATION ABOUT PARENTAL AND FAMILIAL SAMPLES

In some circumstances, it may be helpful for additional family members to undergo testing in order to provide information that can aid in the interpretation of the WES/WGS test results. These Tests could be part of a TRIO Test or as stand-alone targeted testing. PerkinElmer, in consultation with the HCP, will decide if other family members need to be tested. If the HCP recommends testing for additional family members, only the Test performed will be reported. If undergoing a TRIO WES or WGS test, family members will have the option to receive information about secondary findings either as a part of the proband report or as a standalone parental report. A full analysis of the parental samples for secondary findings will only be completed if standalone reports are selected (for an additional charge). If family members elect to receive information about secondary findings either as part of the proband report or as a standalone report, the family member must sign all applicable sections on page 3 and/or 4 of this form.

#### **TEST LIMITATIONS**

Due to current limitations in technology and incomplete knowledge of diseases and genes, some variants may not be detected by the Test ordered. There is a possibility that the Test result that is uninterpretable or of unknown significance may require further testing when more information is gained. In rare circumstances, Test results may be suggestive of a condition different from that which was originally considered for the purpose of consenting to this Test. The Test may also find variants or genes that lead to conditions for which you currently do not have symptoms or may not be related to your current condition.

#### **TEST RISKS**

Patients and family members may experience anxiety before, during, and/or after testing. Testing multiple family members may reveal that familial relationships are not biologically what they were assumed to be. For example, the Test may indicate non-paternity (the stated father of an individual is not the biological father) or consanguinity (the parents of an individual are closely related by blood). These biological relationships may need to be reported to the HCP who ordered the test.

Taking a blood or tissue sample from you and/or your child may lead to mild pain, bruising, swelling, redness, and a slight risk of infection. Light-headedness, fainting or nausea may occur if your HCP collects blood or tissue samples. These side-effects are typically brief and transient, but you should contact your HCP if you and/or your child require treatment. Under some circumstances an additional sample may be required for Tests to be performed.

A positive test result may limit your access to health insurance or life assurance coverage; for example, a life insurance company might ask you to provide genetic information indicating a disorder if this information is available to you. Please refer to information on the Genetic Information Nondiscrimination Act (GINA) and applicable local laws for more information.





### U.S. CLINICAL INFORMED CONSENT FORM

### CONFIDENTIALITY

You have the right to confidential treatment of the Sample and your PHI. Your HCP will provide PerkinElmer with Personal Health Information ("PHI") such as your name, date of birth, gender and clinical symptoms to help track your sample and report results. To maintain confidentiality, the test results will only be released to the referring health care provider, to the ordering laboratory, to the patient/guardian, to other health care providers involved in your diagnosis and treatment, or as otherwise required by law or regulation. Unless required by law, PerkinElmer will not disclose your PHI to any person or entity except with your written consent.

You and your HCP can control how your Sample and PHI are processed. You have the right to request access to your PHI, request corrections of any errors in recorded PHI, or where PHI may be missing or incomplete ask that it be completed. You also have the right to ask that your PHI be erased, subject to law or regulation. You can contact your HCP for such requests and your HCP will contact PerkinElmer, or you can contact PerkinElmer directly by visiting www.perkinelmergenomics.com. If requests for access, correction, completion, or erasure cannot be fulfilled, you will be informed and provided with the reasons why your requests cannot be fulfilled.

#### SAMPLE AND DATA RETENTION

Pursuant to laboratory best practices, your DNA sample will be retained by PerkinElmer for a minimum of two years and then destroyed. Additionally, your PHI, the data from the Tests (including those performed before any withdrawal of consent) and the related reports will be retained by PerkinElmer indefinitely, unless otherwise noted. In some instances, it may be beneficial to you for PerkinElmer to retain your sample for a longer period of time in order to conduct additional testing, and PerkinElmer will do so with appropriate documentation from you or your HCP.

PerkinElmer is requesting consent to keep you and/or your child's anonymized sample and data indefinitely for ongoing test development, scientific research, and/or other activities. This consent is optional, and the Test will be performed whether or not you provide consent to the following:

- PerkinElmer will anonymize and retain your Sample indefinitely for internal quality control, test validation, assay development and improvement. By allowing PerkinElmer to retain your Sample, you understand and agree that you give up any property rights you may have in the Sample and are donating it to PerkinElmer Genetics, Inc. If you withdraw your consent to use of your anonymized sample, no further anonymization will be performed.
  - Check here if you would like to opt out of anonymized sample retention (NY State residents, please see section below). Note, if not checked, this is interpreted as "consent given"
- PerkinElmer will anonymize your data and retain the anonymized data and related anonymized reports from your Tests indefinitely for statistical and quality analysis, research, scientific and technical development, and market research. PerkinElmer may also share your anonymized data and anonymized report with third parties.
  - ☐ Check here if you would like to opt out of anonymized data retention. Note, if not checked, this is interpreted as "consent given"

REQUIRED FOR SAMPLES	S COLLECTED IN NEW YORK STATE OF	NLY
----------------------	----------------------------------	-----

No tests other than those authorized shall be performed on the biological sample submitted for testing, and any material derived from the sample (i.e., DNA); this includes testing for internal research and/or quality control purposes. The sample shall be destroyed no more than 60 days after the sample was taken or at the end of the testing process, whichever occurs later, unless indicated below.

By checking here and signing at right, I consent to PerkinElmer keeping my sample for longer than 60 days, and to using my de-identified sample for internal research and/or quality control purposes. Note, if not checked and signed, this is interpreted as "consent not given."

Patient/Guardian Signature

#### **RESEARCH OPTIONS**

PerkinElmer may collaborate with scientists, researchers and drug developers to advance knowledge of genetic diseases. If there are opportunities to participate in future research relevant to the disease in you and/or your child, PerkinElmer may contact you or your HCP about the development of new testing, drug development, or other treatments. PerkinElmer may also work with scientists or researchers from academic or commercial institutions who have received the necessary approvals to conduct a research study. In some instances, these scientists or researchers may like to contact you directly about your interest in participating in a specific research study.

By checking here I would like to opt out of PerkinElmer being able to provide my contact information to outside researchers to contact me directly about

By checking here I would like to opt out of PerkinElmer being able to provide my contact information to outside researchers to contact me directly abou applicable research studies.

#### WITHDRAWAL OF CONSENT

I understand this consent is voluntary and is valid until I withdraw my consent. I understand I may withdraw my consent to sample and data retention, and to the Test at any time, that PerkinElmer will not perform the Test unless I provide consent to the Test. If I withdraw any consent, it will not affect actions taken before I withdrew my consent, including any anonymization of data or of my Sample. I understand that if I wish to withdraw my consent I should contact PerkinElmer via email at: Genomics@perkinelmer.com or toll-free by telephone +1-866-354-2910 to request withdrawal.

by telephone +1-866-354-2910 to request withdrawal.		•	-
PATIENT CONSENT TO TESTING			
☐ By checking this box I attest:			
I have read and understood the Informed Consent Form in its entire risks associated with genetic testing. I have had the opportunity to a this ICF. My signature below acknowledges my free consent to the health of an unborn child, or the health of other family members.	sk my HCF	questions about the information contained herein,	and understand that I am entitled to a copy of
Patient Signature (or Parent/Guardian if patient is minor)	-	Date	
Patient Name	-	Name and Relationship (Parent/Guar	rdian if patient is minor)
FAMILY MEMBER CONSENT TO TESTING (if applicable	)		
☐ By checking this box I attest: I have read and understood the Infigenetic testing is performed and the risks associated with genetic te and understand that I am entitled to a copy of this ICF. My signature and such testing in no way guarantees my health, the health of an understand the strength of	sting. I have below ack	e had the opportunity to ask my HCP questions abo nowledges my free consent to the Test, and to any a	out the information contained herein,
Family Member Signature	Date Fa	amily Member Name	Relationship to Patient

#### **FAMILY MEMBER CONSENT TO TESTING (if applicable)**

□ By checking this box I attest: I have read and understood the Informed Consent Form in its entirety, including the explanation of why my sample is being tested, how genetic testing is performed and the risks associated with genetic testing. I have had the opportunity to ask my HCP questions about the information contained herein, and understand that I am entitled to a copy of this ICF. My signature below acknowledges my free consent to the Test, and to any additional consents indicated above, and such testing in no way guarantees my health, the health of an unborn child, or the health of other family members.

Family Member Signature Date Family Member Name Relationship to Patient